|View printer-friendly version|
|EPFL to Create "Medtronic Chair in Neuro-Engineering"|
Medtronic Sponsors Research and Education Within EPFL's Campus Biotech Project in Geneva
LAUSANNE/TOLOCHENAZ -- October 31, 2013 -- The Ecole Polytechnique Fédérale Lausanne (EPFL) and global medical technology leader Medtronic have signed a sponsorship agreement to create an EPFL chair in Neuro-Engineering. This chair will be located in Geneva's Campus Biotech, next to the research teams of the Human Brain Project, EPFL's Center for Neuroprosthetics (CNP) and the new Wyss institute for bio- and neuro-engineering. Both partners will benefit from this proximity for groundbreaking innovation in the field of neuroscience.
The Medtronic Chair in Neuro-Engineering is intended to foster fundamental research into the interaction between technology and the brain and the potential to engineer improved devices to alleviate pain, restore health and extend life for those who suffer from degenerative and traumatic brain and spine injury. EPFL's central role in the Human Brain Project, the world's largest research program in this area, offers ideal conditions for this research.
"Developing new therapies and finding solutions to improve the lives of patients is a key component of our Mission and we have great hopes that this partnership with EPFL will contribute to a better understanding of the diseases of the brain and to finding new treatments", says Rob ten Hoedt, Medtronic's Senior Vice President & President for Europe, Middle East, Africa and Canada.
"EPFL has built extensive expertise in the field of neuroprosthetics, to impact the lives of patients with disease and injury through understanding the biological and information networks in the brain and spinal cord; partnership with Medtronic will further our goal of developing advanced neuro-technologies to achieve this", says Jeffrey Hubbell, EPFL's Dean a.i. of the School of Life Sciences. "This is a great opportunity for EPFL with its long tradition for technological innovation to partner with Medtronic, one of the world's leading manufacturers of biomedical devices" commented Demetri Psaltis, Dean of the Engineering School.
Medtronic pioneered the field of neuromodulation, the targeted and regulated delivery of electrical pulses and pharmaceuticals to specific sites in the nervous system. The company's Neuromodulation business includes deep brain stimulation (DBS) therapy, which uses a surgically implanted medical device to deliver mild electrical pulses to precisely targeted areas of the brain for the treatment of common movement disorders; and neurostimulation therapy for chronic pain, which uses a device placed under a patient's skin to deliver mild electrical impulses to the spinal cord, acting to block pain signals from going to the brain.
The School's unique structure fosters trans-disciplinary research and promotes partnerships with other institutions. It continuously combines fundamental research and engineering.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.